Open original FDA record ↗Recall record
- FDA identifier
- Z-0722-2007
- Company in FDA record
- Abbott Laboratories Inc.
- FDA classification date
- Apr 5, 2007
- First observed by MedTech Watch
- Nov 16, 2026
- Latest observed content change
- Nov 20, 2026
- Recall classification
- Unknown — no matched enforcement classification
Reason stated in the source
Patient results are falsely decreased by up to 15% at these levels: 1) Serum Plasma phosphorus greater than 8.0 mg/dL (2.60 mmol/L) 2) Urine phosphorus greater than 80.0 mg/dL (25.80 mmol/L)
Source facts
- Action
- A Product Correction letter dated January 30, 2007 provided to all Clinical Chemistry Phosphorus customers that have received lot numbers 42020HW00 and 44037HW00 stating that patient results are falsely decreased by up to 15% at these levels: Serum/Plasma phosphorus greater than 8.0 mgldL (2.60 mmol/L) and Urine phosphorus greater than 80.0 mg/dl. (25.80 mmol/L). Modified linearity ranges are provided in the letter that are to be implemented when using the two lots. Instructions are also provided for changing the linearity range on the Architect cSystem as well as the Aeroset System. Customers are instructed that If they have forwarded any of Information the Clinical Chemistry Phosphorus lots listed above to another laboratory to provide a copy of this letter to them. A customer response form is provided.
- Initiated
- 2007-01-30
- Root cause
- Other
- Terminated
- 2011-08-10
- Distribution
- Worldwide, including USA, Canada, Trinidad & Tobago, Bahamas, Panama, Cayman Islands, Jamaica
- Recall number
- Z-0722-2007
- Recall status
- Terminated
- CDRH record ID
- 50375
- FDA classified
- 2007-04-05
- Recall event number
- 37334